TD Asset Management
CRL icon

TD Asset Management’s Charles River Laboratories CRL Stock Holding History

TD Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
56,679
+35,222
+164% +$6.27M 0.01% 601
2026
Q1 		$3.7M Buy
21,457
+12,980
+153% +$2.41M ﹤0.01% 843
2025
Q4 		$1.69M Sell
8,477
-117
-1% -$21.2K ﹤0.01% 1019
2025
Q3 		$1.34M Sell
8,594
-330
-4% -$52.4K ﹤0.01% 1040
2025
Q2 		$1.35M Sell
8,924
-85
-0.9% -$11.3K ﹤0.01% 1017
2025
Q1 		$1.36M Sell
9,009
-4,978
-36% -$835K ﹤0.01% 1037
2024
Q4 		$2.58M Buy
13,987
+60
+0.4% +$11.6K ﹤0.01% 940
2024
Q3 		$2.76M Sell
13,927
-96,502
-87% -$20.1M ﹤0.01% 929
2024
Q2 		$22.8M Sell
110,429
-22,464
-17% -$5.09M 0.02% 463
2024
Q1 		$36M Buy
132,893
+98,371
+285% +$23.5M 0.03% 353
2023
Q4 		$8.16M Sell
34,522
-2,790
-7% -$549K 0.01% 652
2023
Q3 		$7.31M Sell
37,312
-5,811
-13% -$1.19M 0.01% 645
2023
Q2 		$9.07M Sell
43,123
-8,722
-17% -$1.74M 0.01% 621
2023
Q1 		$10.5M Buy
51,845
+9,260
+22% +$2.1M 0.01% 593
2022
Q4 		$9.28M Buy
42,585
+2,932
+7% +$640K 0.01% 615
2022
Q3 		$7.53M Sell
39,653
-22,434
-36% -$4.84M 0.01% 658
2022
Q2 		$13.3M Buy
62,087
+21,360
+52% +$5.22M 0.02% 533
2022
Q1 		$11.6M Buy
40,727
+137
+0.3% +$42.2K 0.01% 623
2021
Q4 		$15.3M Sell
40,590
-10,859
-21% -$4.22M 0.01% 577
2021
Q3 		$21.2M Sell
51,449
-46
-0.1% -$19.1K 0.02% 463
2021
Q2 		$21M Buy
51,495
+14,253
+38% +$4.76M 0.02% 474
2021
Q1 		$10.8M Sell
37,242
-48,611
-57% -$13.5M 0.01% 615
2020
Q4 		$21.5M Sell
85,853
-75,394
-47% -$18M 0.03% 422
2020
Q3 		$36.5M Sell
161,247
-31,807
-16% -$6.6M 0.05% 269
2020
Q2 		$33.7M Buy
193,054
+3,198
+2% +$510K 0.05% 262
2020
Q1 		$24M Buy
189,856
+87,671
+86% +$13.1M 0.04% 301
2019
Q4 		$15.6M Buy
102,185
+32,478
+47% +$4.5M 0.02% 436
2019
Q3 		$9.23M Sell
69,707
-6,067
-8% -$813K 0.01% 543
2019
Q2 		$10.8M Buy
+75,774
New +$10.3M 0.02% 502

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TD Asset Management's CRL Position: Q2 2026 in Review

TD Asset Management increased its Charles River Laboratories (CRL) stake by 164% in Q2 2026, buying an estimated $6.27M and bringing the position to 56,679 shares worth $12.9M. The position accounts for 0.01% of the portfolio, ranked #601.

TD Asset Management first reported a position in CRL in Q2 2019 and has held it in 29 quarters since. The position peaked at $36.5M in Q3 2020. 432 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • TD Asset Management held 56,679 shares of Charles River Laboratories worth $12.9M as of Q2 2026.
  • TD Asset Management bought 35,222 Charles River Laboratories shares in Q2 2026, an estimated $6.27M.
  • Charles River Laboratories made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #601 holding.
  • TD Asset Management first reported a position in Charles River Laboratories in Q2 2019 and has held it in 29 quarters since.
  • TD Asset Management's Charles River Laboratories position peaked at $36.5M in Q3 2020.
  • 432 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.